TI A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
AU Rouse DJ; Hirtz DG; Thom E; Varner MW; Spong CY; Mercer BM; Iams
JD; Wapner RJ; Sorokin Y; Alexander JM; Harper M; Thorp JM Jr; Ramin
SM; Malone FD; Carpenter M; Miodovnik M; Moawad A; O'Sullivan MJ;
Peaceman AM; Hankins GD; Langer O; Caritis SN; Roberts JM
SO N Engl J Med. 2008 Aug 28;359(9):895-905.
BACKGROUND: Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy. METHODS: In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age. RESULTS: A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23). However, in a prespecified secondary analysis, moderate or severe cerebral palsy occurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95). The risk of death did not differ significantly between the groups (9.5% vs. 8.5%; relative risk, 1.12; 95% CI, 0.85 to 1.47). No woman had a life-threatening event. CONCLUSIONS: Fetal exposure to magnesium sulfate before anticipated early preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.)
AD University of Alabama at Birmingham, Birmingham, USA. drouse@uab.edu
PMID 18753646
AU Rouse DJ; Hirtz DG; Thom E; Varner MW; Spong CY; Mercer BM; Iams
JD; Wapner RJ; Sorokin Y; Alexander JM; Harper M; Thorp JM Jr; Ramin
SM; Malone FD; Carpenter M; Miodovnik M; Moawad A; O'Sullivan MJ;
Peaceman AM; Hankins GD; Langer O; Caritis SN; Roberts JM
SO N Engl J Med. 2008 Aug 28;359(9):895-905.
BACKGROUND: Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy. METHODS: In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age. RESULTS: A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23). However, in a prespecified secondary analysis, moderate or severe cerebral palsy occurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95). The risk of death did not differ significantly between the groups (9.5% vs. 8.5%; relative risk, 1.12; 95% CI, 0.85 to 1.47). No woman had a life-threatening event. CONCLUSIONS: Fetal exposure to magnesium sulfate before anticipated early preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.)
AD University of Alabama at Birmingham, Birmingham, USA. drouse@uab.edu
PMID 18753646
الأربعاء 15 يوليو 2015, 11:21 pm من طرف MOHAMMED ABD ELFATAH
» Diseases and Disorders in Infancy and Early Childhood
الإثنين 15 يونيو 2015, 9:34 pm من طرف MOHAMMED ABD ELFATAH
» كيفية التسجيل والإستعداد لامتحان ال Mccee الكندي
الأربعاء 06 مايو 2015, 2:06 pm من طرف عبدالحليم ابداح
» MRCP 2 Practice Papers
الجمعة 31 أكتوبر 2014, 6:08 pm من طرف Dr .ibrahim
» إمتحانات السنوات السابقة لل MRCP part 1
الأحد 03 أغسطس 2014, 10:44 pm من طرف الحاج منصور
» oxford handbooks Series
الإثنين 02 يونيو 2014, 12:25 pm من طرف ًWIFAG
» ادق برنامج عيادات لادارة عيادتك الخاصة
الإثنين 05 مايو 2014, 11:15 am من طرف petra2
» لعلاج السحر والمس والعين
الأربعاء 29 يناير 2014, 3:09 pm من طرف الطبيب الروحاني
» للحصول على ( الزمالة البريطانية لطب الاطفال MRCPCH ) بكل سهولة من CONNECT CENTER
الخميس 23 يناير 2014, 7:34 pm من طرف connect center
» الأن ولفترة محدووودة ( كورس زمالة الباطنة MRCP ) بارخص الاسعاااار من connect center
الخميس 23 يناير 2014, 6:08 pm من طرف connect center